# Global Trial in APG2575 for Patients With CLL/SLL

> **NCT06104566** · PHASE3 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 400 (estimated)

## Conditions studied

- CLL/SLL

## Interventions

- **DRUG:** lisaftoclax +BTK inhibitor
- **DRUG:** BTK inhibitor

## Key facts

- **NCT ID:** NCT06104566
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2025-10-20
- **Final completion:** 2027-10-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06104566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06104566, "Global Trial in APG2575 for Patients With CLL/SLL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06104566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*